Key Updates in the WADA 2025 Prohibited List: Implications for Competitive Sports
DOI:
https://doi.org/10.12775/QS.2025.42.61192Keywords
WADA, World Anti-Doping Agency, Prohibited List, Prohibited List 2025, Doping, OlympicsAbstract
The 2025 revision of the World Anti-Doping Agency (WADA) Prohibited List introduces significant updates grounded in recent pharmacological developments, emerging therapeutic compounds, and shifting patterns of misuse in sport. This scientific brief outlines key changes, including the addition of novel agents such as ryanodine receptor-1-calstabin complex stabilizers (e.g., S-107, ARM210) to the S0 category, the estrogen receptor degrader elacestrant to S4.2, and MOTS-c to the metabolic modulators section (S4.4). Other revisions include formal recognition of insulin mimetics (S519, S597), the naming of xipamide as a masking agent, and stricter dosing intervals for inhaled formoterol. Classification updates affect stimulants such as hydrafinil (reallocated to S6.A), and newly listed specified stimulants including midodrine and tesofensine. The revised policy also clarifies the permissibility of blood donation via apheresis procedure under strict oversight and introduces notable sport-specific changes, which is removal of β-blockers from the Prohibited List for selected skiing and snowboarding disciplines, following recommendations by the International Ski Federation (FIS). These changes underscore WADA’s commitment to preemptive regulation based on emerging risks, ensuring fairness and athlete safety. Where applicable, clinical rationale, therapeutic use implications, and detection methodologies are discussed to support implementation and compliance across sports.
References
1. World Anti-Doping Agency. The 2025 Prohibited List. Montreal, QC: WADA; 2024 Sep 11 [cited 2025 May 16]. Available from: https://www.wada-ama.org/en/resources/science-medicine/prohibited-list
2. World Anti-Doping Agency. The 2024 Prohibited List. Montreal, QC: WADA; 2023 Sep 29 [cited 2025 May 16]. Available from: https://www.wada-ama.org/en/resources/science-medicine/prohibited-list
3. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010 Apr;95(4):1533–43. doi: 10.1210/jc.2009-1579. PMID: 20139230.
4. Mei Y, Xu L, Kramer HF, Tomberlin GH, Townsend C, Meissner G. Stabilization of the skeletal muscle ryanodine receptor ion channel-FKBP12 complex by the 1,4-benzothiazepine derivative S107. PLoS One. 2013 Jan 17;8(1):e54208. doi: 10.1371/journal.pone.0054208. PMID: 23326577.
5. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W, Shiomi T, Zalk R, Lacampagne A, Marks AR. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 2011 Feb 2;14(2):196–207. doi: 10.1016/j.cmet.2011.05.014. PMID: 21803296.
6. Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014 Aug 5;101:66–83. doi: 10.1016/j.jpba.2014.05.020.
7. Capogrosso RF, Mantuano P, Uaesoontrachoon K, Cozzoli A, Giustino A, Dow T, et al. Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy. FASEB J. 2018 Feb;32(2):1025–43. doi: 10.1096/fj.201700182RRR. Epub 2018 Jan 3. PMID: 29097503; PMCID: PMC5888399.
8. Todd JJ, Lawal TA, Chrismer IC, Kokkinis A, Grunseich C, Jain MS, et al. Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial. EClinicalMedicine. 2024 Jan 25;68:102433. doi: 10.1016/j.eclinm.2024.102433. PMID: 38318125; PMCID: PMC10839573.
9. Smit DL, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. Neth J Med. 2018 May;76(4):167. PMID: 29845939.
10. Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models. Clin Cancer Res. 2017 Aug 15;23(16):4793–804. doi: 10.1158/1078-0432.CCR-16-2561. Epub 2017 May 4. PMID: 28473534.
11. Varella L, Cristofanilli M. Evaluating elacestrant in the management of ER-positive, HER2-negative advanced breast cancer: evidence to date. Onco Targets Ther. 2023 Mar 23;16:189–96. doi: 10.2147/OTT.S400563. PMID: 36993871; PMCID: PMC10041978.
12. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010 Apr;95(4):1533–43. doi: 10.1210/jc.2009-1579. Epub 2010 Feb 5. PMID: 20139230.
13. Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Mayo Clin Proc. 2003 Jan;79(1):203–5.
14. Rambhatla A, Mills JN, Rajfer J. The role of estrogen modulators in male hypogonadism and infertility. Rev Urol. 2016;18(2):66–72. doi: 10.3909/riu0711. PMID: 27601965; PMCID: PMC5010627.
15. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443–54. doi: 10.1016/j.cmet.2015.02.009. PMID: 25738459; PMCID: PMC4350682.
16. Di Girolamo FG, Biasinutto C, Mangogna A, Fiotti N, Vinci P, Pisot R, et al. Metabolic consequences of anabolic steroids, insulin, and growth hormone abuse in recreational bodybuilders: implications for the World Anti-Doping Agency Passport. Sports Med Open. 2024 Mar 27;10(1):28. doi: 10.1186/s40798-024-00697-6. PMID: 38536564; PMCID: PMC10973313.
17. Kavouras SA, Panagiotakos DB, Pitsavos C, Chrysohoou C, Anastasiou CA, Lentzas Y, et al. Physical activity, obesity status, and glycemic control: the ATTICA study. Med Sci Sports Exerc. 2007 Apr;39(4):606–11. doi: 10.1249/mss.0b013e31803084eb. Erratum in: Med Sci Sports Exerc. 2007 Nov;39(11):2093. PMID: 17414797.
18. Ran N, Lin C, Leng L, Han G, Geng M, Wu Y, et al. MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice. EMBO Mol Med. 2021 Feb 5;13(2):e12993. doi: 10.15252/emmm.202012993. Epub 2020 Dec 18. PMID: 33337582; PMCID: PMC7863382.
19. Kumagai H, Coelho AR, Wan J, Mehta HH, Yen K, Huang A, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021 Apr 1;320(4):E680–90. doi: 10.1152/ajpendo.00275.2020. Epub 2021 Feb 8. PMID: 33554779; PMCID: PMC8238132.
20. Gao Y, Wei X, Wei P, Lu H, Zhong L, Tan J, et al. MOTS-c functionally prevents metabolic disorders. Metabolites. 2023 Jan 13;13(1):125. doi: 10.3390/metabo13010125. PMID: 36677050; PMCID: PMC9866798.
21. United States Anti-Doping Agency (USADA). Athlete Advisory: What’s New on the 2025 WADA Prohibited List? [Internet]. 2024 Sep 29 [cited 2025 May 16]. Available from: https://www.usada.org/athlete-advisory/new-2025-wada-prohibited-list/
22. Thomas A, Krombholz S, Breuer J, Walpurgis K, Thevis M. Insulin-mimetic peptides in sports drug testing. Drug Test Anal. 2023 Sep 11. doi: 10.1002/dta.3572. Epub ahead of print.
23. Gómez-Guerrero NA, González-López NM, Zapata-Velásquez JD, Martínez-Ramírez JA, Rivera-Monroy ZJ, García-Castañeda JE. Synthetic peptides in doping control: a powerful tool for an analytical challenge. ACS Omega. 2022 Oct 21;7(43):38193–206. doi: 10.1021/acsomega.2c05296. PMID: 36340120; PMCID: PMC9631397
24. Jensen M, Hansen B, De Meyts P, Schäffer L, Ursø B. Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J Biol Chem. 2007 Nov 30;282(48):35179–86. doi: 10.1074/jbc.M704599200. Epub 2007 Oct 9. PMID: 17925406.
25. Xipamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drug Evaluations. 1985;30:313–32. doi: 10.2165/00003495-198530040-00003.
26. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. 15th ed. Amsterdam: Elsevier; 2006. Entry: Xipamide.
27. Cadwallader AB, de la Torre X, Tieri A, Botrè F. The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis. Br J Pharmacol. 2010 Sep;161(1):1–16. doi: 10.1111/j.1476-5381.2010.00789.x. PMID: 20718736; PMCID: PMC2962812.
28. World Anti-Doping Agency. The World Anti-Doping Code: The 2004 Prohibited List International Standard. Montreal: WADA; 2004 Mar 17. Effective as of 26 Mar 2004.
29. Mortier A, Khoudary J, van Dooslaer de Ten Ryen S, Lannoy C, Benoit N, Antoine N, et al. Effects of plasmapheresis frequency on health status and exercise performance in men: A randomized controlled trial. Vox Sang. 2024 Feb;119(2):134–43. doi: 10.1111/vox.13569. Epub 2023 Nov 24. PMID: 37997609.
30. Mørkeberg J. Blood manipulation: current challenges from an anti-doping perspective. Hematology Am Soc Hematol Educ Program. 2013 Dec 6;2013(1):627–32. doi: 10.1182/asheducation-2013.1.627.
31. Jeppesen JS, Jessen S, Thomassen M, Backer V, Bangsbo J, Hostrup M. Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists. Scand J Med Sci Sports. 2023 Oct 25. doi: 10.1111/sms.14500.
32. Hostrup M, Hansen ESH, Rasmussen SM, Jessen S, Backer V. Asthma and exercise-induced bronchoconstriction in athletes: Diagnosis, treatment, and anti-doping challenges. Scand J Med Sci Sports. 2023 Mar 25. doi: 10.1111/sms.14358.
33. Andersen AB, Jacobson GA, Bejder J, Premilovac D, Richards SM, Rasmussen JJ, et al. An abductive inference approach to assess the performance-enhancing effects of drugs included on the World Anti-Doping Agency Prohibited List. Sports Med. 2021 Jun;51(6):1233–41. doi: 10.1007/s40279-021-01450-9. PMID: 33811295.
34. Vanhee C, Tuenter E, Kamugisha A, Canfyn M, Moens G, Courselle P, et al. Identification and quantification methodology for the analysis of suspected illegal dietary supplements: Reference standard or no reference standard, that’s the question. J Forensic Toxicol Pharmacol. 2018;7(1):156. doi: 10.4172/2325-9841.1000156.
35. Dunn D, Hostetler G, Iqbal M, Marcy VR, Lin YG, Jones B, et al. Wake promoting agents: search for next generation modafinil, lessons learned: part III. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3751-3. doi: 10.1016/j.bmcl.2012.04.031. PMID: 22546675.
36. World Anti-Doping Agency. Summary of major modifications and explanatory notes: 2025 Prohibited List [Internet]. Montreal: WADA; 2024 [cited 2025 May 16]. Available from: https://www.wada-ama.org/sites/default/files/2024-09/2025_list_explanatory_note_en_final_11_september_2024.pdf
37. Hydrafinil (Fluorenol): A Modafinil Analogue with Questionable Safety [Internet]. Mental Health Daily; 2015 Dec 23 [cited 2025 May 16]. Available from: https://mentalhealthdaily.com/2015/12/23/hydrafinil-fluorenol-a-modafinil-analogue-with-questionable-safety/
38. McTavish D, Goa KL. Midodrine: a review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs. 1989;38(5):757–77. doi: 10.2165/00003495-198938050-00007.
39. Perez CI, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024 Apr 24;19(4):e0300544. doi: 10.1371/journal.pone.0300544. PMID: 38656972; PMCID: PMC11042726.
40. Ota T, Yamamuro K, Okazaki K, Kishimoto T. Evaluating guanfacine hydrochloride in the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients: design, development and place in therapy. Drug Des Devel Ther. 2021 May 11;15:1965-9. doi: 10.2147/DDDT.S221126. PMID: 34007156; PMCID: PMC8123957.
41. Yu S, Shen S, Tao M. Guanfacine for the treatment of attention-deficit hyperactivity disorder: an updated systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2023 Mar;33(2):40-50. doi: 10.1089/cap.2022.0038. PMID: 36944092.
42. Álamo C, López-Muñoz F, Sánchez-García J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention-deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr. 2016;44(3):107-21.
43. Ergen E, Hazir T, Celebi M, Kin-Isler A, Aritan S, Yaylıoglu VD, Guner R, Acikada C, Cinemre A. Effects of beta-blockers on archery performance, body sway and aiming behaviour. BMJ Open Sport Exerc Med. 2021 May 7;7(2):e001071. doi: 10.1136/bmjsem-2021-001071. PMID: 34040794; PMCID: PMC8108660.
44. Videman T, Sonck T, Jänne J. The effect of beta-blockade in ski-jumpers. Med Sci Sports. 1979 Fall;11(3):266-9. PMID: 522637.
45. Schmid P. [Use of beta receptor blockers in performance sports]. Wien Med Wochenschr. 1990 Apr 1;140(6-7):184-8. German. PMID: 1971982.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maciej Michalik, Tomasz Lorenc, Mateusz Muras, Krzysztof Marcinkowski, Natalia Mikszta, Jakub Mikszta, Julia Marcinkowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 19
Number of citations: 0
